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Proteomic profiling of peripheral blood
neutrophils identifies two inflammatory
phenotypes in stable COPD patients
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Abstract
Background: COPD is a heterogeneous chronic inflammatory disease of the airways and it is well accepted that
the GOLD classification does not fully represent the complex clinical manifestations of COPD and this classification
therefore is not well suited for phenotyping of individual patients with COPD. Besides the chronic inflammation in
the lung compartment, there is also a systemic inflammation present in COPD patients. This systemic inflammation
is associated with elevated levels of cytokines in the peripheral blood, but the precise composition is unknown.
Therefore, differences in phenotype of peripheral blood neutrophils in vivo could be used as a read out for the
overall systemic inflammation in COPD.
Method: Our aim was to utilize an unsupervised method to assess the proteomic profile of peripheral neutrophils
of stable COPD patients and healthy age matched controls to find potential differences in these profiles as read-out
of inflammatory phenotypes. We performed fluorescence two-dimensional difference gel electrophoresis with the
lysates of peripheral neutrophils of controls and stable COPD patients.
Results: We identified two groups of COPD patients based on the differentially regulated proteins and hierarchical
clustering whereas there was no difference in lung function between these two COPD groups. The neutrophils
from one of the COPD groups were less responsive to bacterial peptide N-formyl-methionyl-leucyl-phenylalanine
(fMLF).
Conclusion: This illustrates that systemic inflammatory signals do not necessarily correlate with the GOLD
classification and that inflammatory phenotyping can significantly add in an improved diagnosis of single
COPD patients.
Trial registration: Clinicaltrials.gov: NCT00807469 registered December 11th 2008
Keywords: COPD, Proteomics profile, Neutrophil, Systemic inflammation, Inflammatory phenotype
Background
Chronic Obstructive Pulmonary Disease (COPD) is charac-
terized by irreversible airflow limitation [1] and is a leading
cause of mortality and morbidity worldwide [2]. Cigarette
smoking is the most important risk factor for the
development of COPD in the western world. According to
the Global Initiative for Chronic Obstructive Pulmonary
Disease (GOLD) the diagnosis and severity of COPD is
assessed using lung function measurements: Forced
Expiratory Volume (FEV1) and Forced Vital Capacity
(FVC) [3, 4]. It is well accepted that these spirometry
measurements are insufficient, mainly because spirometry
data alone poorly correlate with symptoms and health
status [5, 6].
Many studies have been focused on the identification
of disease phenotypes in COPD and have searched for
individual and/or combined biomarkers using data from
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exhaled breath condensate [7], lung biopsies [8–10],
induced sputum [11], plasma [12–14] and bronchoalveo-
lar lavage (BAL) fluid [15]. Unfortunately, bonchoscopy
to obtain lung tissue and BAL fluid and to a lesser extent
induced sputum are invasive procedures and are there-
fore difficult to perform regularly in COPD patients es-
pecially in the more severe phenotypes. Therefore, there
is an unmet clinical need for objective disease markers
identifying COPD phenotypes that can be obtained with
non invasive methods.
The airflow limitation in COPD is usually progressive
and is associated with an abnormal inflammatory re-
sponse in the lungs. This inflammation in the lung is
characterized by an accumulation of neutrophils, macro-
phages and lymphocytes [16]. Besides the inflammation
in the lung there is also a systemic inflammation that is
normally illustrated by elevated levels of cytokines
(TNFα, IL-8) and CRP in the peripheral blood of COPD
patients [17, 18]. Oudijk et al. [19] have shown that per-
ipheral blood neutrophils from COPD patients were
characterized by modulated gene expression of IL-1β,
IL-1Rα, MIP-1β and CD83 [19], which correlated with a
decreased FEV1. We have shown that pro-inflammatory
cytokines such as GM-CSF and TNFα can both syner-
gize and antagonize inflammatory signaling pathways in
neutrophils [20]. Therefore, measurements of individual
cytokines using multiplex assays without determining
their natural modulators in clinical samples could lead
to wrong conclusions. And, therefore, modulation of
protein expression in peripheral blood neutrophils as
read-out of the combined action of pro- and anti-
inflammatory cytokines on leukocytes could be a better
approach to measure systemic inflammation in COPD
patients.
We collected peripheral blood neutrophils from
COPD patients to perform proteomics analysis. We
hypothesize that the net result of multiple cytokines on
the change in phenotype of peripheral blood neutro-
phils in vivo can be used as a read out for the overall
inflammatory status of the COPD patients. We used
the unbiased fluorescence two-dimensional (2D) differ-
ence gel electrophoresis (DIGE) method to analyze pro-
tein expression of peripheral blood neutrophils from
COPD patients and healthy aged matched controls.
Methods
Patients and healthy controls
We included 41 stable COPD patients (age 40–75
years) with a smoking history of more than 10 pack
years and a ratio of FEV1 to forced vital capacity (FVC)
below 70% after bronchodilator use, as described by the
global initiative for chronic obstructive lung disease
(GOLD) [21]. COPD patients with a history of other in-
flammatory diseases, acute pulmonary disease or other
infections, treatment with antibiotics or corticosteroids
8 weeks to inclusion, recent diagnosis of cancer and a
history of asthma were excluded. Control subjects were
healthy age-matched subjects with normal lung func-
tion and no medical history of pulmonary disease. This
study was approved by the medical ethical committee
and all study subjects provided written informed con-
sent. This study is based on data collected as part of a
bi-center cross-sectional study performed by University
Medical Centers of Utrecht and Groningen, with trial
register numbers NCT00850863 and NCT00807469
(www.clinicaltrials.gov).
Reagents and antibodies
Ficoll-Paque was obtained from GE Healthcare (Uppsala,
Sweden). Human Serum Albumin (HSA) was from
Sanquin (Amsterdam, the Netherlands). HEPES-buffered
RPMI 1640 was from Invitrogen (Carlsbad, CA, USA).
Dihydrorhodamine 123 (DHR) was purchased from Sigma
Aldrich (St. Louis, MO, USA) and dissolved in DMSO at a
concentration of 3,33 mg/ml and stored at −20 °C. Platelet
Activating Factor (PAF) and fMLF were purchased from
Sigma Chemical Co (St. Louis, MO, USA). The VIM12
(CD11b, Mac-1, IgG1) was obtained from Caltag Invitro-
gen (Carlsbad, CA, USA). For flow cytometry staining we
used the antibodies CD18 (clone L130); CD15 (clone
MMA); CD32 (clone FLI8.26), CD35 (clone E11), CD44
(clone 515), CD63 (clone H5C6) and CD16 (clone 3G8)
obtained from BD Pharmingen (San Diego, CA, USA).
CD11b (clone 2LPM19c) was from DAKO (Copenhagen,
Denmark), CD66b (clone 80H3) was from Cytognos
(Salamanca, Spain), CXCR1 (clone 42705), CXCR2 (clone
48311) and CD45 (clone 2D1) were from R&D systems
(Europe, UK) and CD64 (clone 10.1) was from AbD
Serotec (Oxford, UK). CD29 (clone N29) was purchased
from Millipore. All other chemicals were reagent grade.
Granulocyte isolation
Granulocytes were isolated from whole blood anticoagu-
lated with sodium-heparin from COPD patients or age-
matched healthy control subjects. Blood was diluted 2.5:1
with PBS containing trisodium citrate (0.4%w/v, pH 7.4)
and human pasteurized plasma-protein solution (4 g/L).
The granulocytes were separated from the mononuclear
cells by centrifugation using Ficoll-Paque. Erythrocytes
were lysed in isotonic ice-cold NH4Cl solution (8.3 g/L
NH4Cl, 1 g/L KHCO3 and 37 mg/L EDTA) followed by
centrifugation at 4 °C. After isolation, granulocytes were
washed in PBS containing trisodium citrate (0.4%w/v,
pH 7.4) and human pasteurized plasma-protein solution
(4 g/L) and resuspended in HEPES buffered RPMI 1640
supplemented with 0.5% (w/v) HSA. Purity of neutrophils
was >95% with eosinophils as major contaminant.
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Protein extract preparation
Neutrophils (5 × 106/mL) in HEPES buffered RPMI
1640 supplemented with 0.5% (w/v) HSA were incu-
bated for 15 min at 37 °C. Subsequently, neutrophils of
COPD patients and healthy age-matched controls were
immediately prepared for protein extracts. The neutro-
phils (1 × 107/sample) were washed twice with sucrose
buffer (0.34 M sucrose, 1 mM EDTA, 10 mM Tris) and
lysed in lysis buffer (10 mM Tris pH 7.4, 10% glycerol,
1% NP40, 50 mM NaF, 20 mM tetra-Na pyrophosphate,
1 mM DTT, 2 mM vanadate, 1 mM PMSF, 2 mM DFP
and 1 × Complete EDTA-free protease inhibitor cocktail
tablet (Roche)). Proteins were precipitated with 80%
acetone and dissolved in labeling buffer (8 M Urea,
2 M Thiourea, 4% CHAPS, 10 mM Tris pH 8.5).
CyDye labeling
The DIGE technology is an unbiased approach to iden-
tify differences in protein expression and the use of an
internal standard enables identification of protein differ-
ences as small as 10% [22]. Protein extracts were labeled
using the fluorescent cyanine dyes developed for 2D-
DIGE technology (GE Healthcare) following manufac-
turer’s protocol. Protein extracts (30 μg) were labeled
with 300 pmol of fluorescent dye (Cy2 or Cy3 or Cy5).
Protein samples from COPD patients and healthy age-
matched control were randomly labeled with Cy3 or
Cy5. To exclude the effects of preferential labeling each
dye was used a similar number of times in each group.
An internal standard, created by pooling 15 μg of each
protein sample, was labeled with Cy2. Labeling was
stopped by adding lysine and equal volume of 2 × IEF
buffer (8 M Urea, 2 M Thiourea, 4% CHAPS, 300 mM
DTT, 1.0% IPG buffer 3-10NL, 0.004% Bromophenol-
blue) to each sample.
2D-gel electrophoresis and analysis
Two protein samples (Cy3 and Cy5) were mixed with the
Cy2-labeled internal control. Protein samples were pas-
sively rehydrated into 24 cm pH 3-10 NL strips (GE
Healthcare, Uppsala, Sweden) for 10 h followed by isoelec-
tric focusing using a manifold-equipped IPGphor IEF unit
(GE Healthcare) according to the manufacturer’s protocol.
The cysteine sulfhydryls were reduced with 1.0% DTT and
carbamidomethylated with 2.5% Iodoacetamide in equili-
bration buffer (30% glycerol, 2% SDS, 6 M urea, 75 mM
Tris, pH 8.8). Second dimensional SDS-PAGE was per-
formed on hand-cast 12% SDS-PAGE gels using low fluor-
escence glass plates. Electrophoresis was carried out at 0.2
watts/gel for 2 h followed by 1 watts/gel until completion
using an Ettan DALT-12 unit (GE Healthcare). Gels were
scanned using a Typhoon 9410 imager at 100 μm reso-
lution (GE Healthcare). Scan settings were optimized for a
maximal signal of 85.000 counts. The gel images were
cropped using ImageQuantTL 2003 (GE Healthcare),
spot detection was performed with DeCyder 7.0 DIA
(Difference In-gel Analysis) software (GE Healthcare)
and gel images were matched using DeCyder 7.0 BVA
(Biological Variation Analysis) software (GE Health-
care). Proteins present in >70% of the spot maps were
included in the analysis and proteins with an average
ratio of at least 1.5 and p < 0.05 were considered
significant.
Flow cytometry analysis
Blood was collected from COPD patients in sterile
collection tubes containing sodium heparin as an anti-
coagulant. The erythrocytes from the whole blood were
lysed with ice-cold NH4Cl. The leukocytes were washed
once with ice cold NH4Cl and centrifuged at 4 °C.
Hereafter, the cells were washed and resuspended in
PBS buffer for FACS analysis in (PBS containing 0.32%
(w/v) sodium citrate and human pasteurized plasma so-
lution (4 g/L)). Unstmulated leukocytes (1.25 × 105
cells) were stained with CD11b, CD18, CD15, CD66b,
CXCR1, CD64, CD29 and CD32 in combination with
CD16 for 30 min at 4 °C, washed once in PBS buffer
and resuspended in PBS buffer. Cells were analyzed on
a FACs Calibur flow-cytometer (Becton Dickinson,
Mountain View, CA, USA). Neutrophils were identified
according to their specific side scatter and forward
scatter signals and CD16 expression (for the gating
strategy see Fig. 1). The experiments were controlled
by staining cells with isotype control antibodies (see
e.g. Fig. 5).
For staining with antibodies against the active form of
FcγRII we used the directly FITC-labelled monoclonal
phage antibody A17, as described previously [23]. In
short, whole blood was stimulated in the presence or
absence 10 -6 M of fMLF for 5 min at 37 °C. After stimu-
lation the A17 antibody and CD11b PE antibody were
added to 50 μl whole blood and incubated for 60 min at
4 °C. After staining erythrocytes were lysed and expres-
sion of active FcγRII (A17) and CD11b were measured
on a FACS Calibur (Becton Dickinson, Mountain View,
CA, USA).
Respiratory burst assay
After lysis of the erythrocytes, the leukocytes were washed
and resuspended in HEPES buffer (20 mM HEPES,
132 mM NaCl, 6 mM KCl, 1.2 mM KH2PO4, 1 mM
MgSO4), supplemented with 5 mM glucose, 1 mM CaCl2,
and 0.5% (w/v) human serum albumin (HSA). The leuko-
cytes (2.0 × 106 cells/ml) were primed with 10 -6 M PAF at
37 °C. After 2 min DHR was added to a final concentra-
tion of 1 μMol/L and incubated for 5 min. In some experi-
ments the cells were stimulated with fMLF (10 -6 M) or
VIM12 (10 μg/ml) at 37 °C in the dark. After stimulation
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the cells were washed with 3 ml of cold PBS supplemented
with 1% (w/v) HSA and samples were kept at 4 °C in the
dark. The production of reactive oxygen species (ROS)
was analyzed with a FACs Calibur flow cytometer (Becton
Dickinson, Mountain View, CA, USA). Neutrophils were
identified by their specific side scatter and forward scatter
signals.
Multiplex analysis
Plasma from COPD patients and healthy age-matched
controls were obtained from blood anti-coagulated with
EDTA after immediate centrifugation (2000 g at 4 °C for
10 min) and were stored at −80 °C until analysis. Concen-
trations of cytokines were determined by applying the
Luminex platform as has been described before [24].
Statistical analysis
Statistical analysis of 2D-DIGE spot intensity was
performed using DeCyder 7.0 BVA or EDA software
(GE Healthcare, Uppsala, Sweden). Other statistical
analyses were performed if appropriate using either an
independent sample t tests or an ANOVA with statis-
tical software package IBM SPSS 20.
Results
Patient characteristics
In total, 41 at inclusion stable COPD patients and 7
healthy age-matched controls were included in this
study. Fourteen COPD patients were currents smokers,
whereas 27 of the COPD patients were ex-smokers. Four
of the healthy controls were never smokers and 3 were
ex-smokers. Details of the COPD patients and the
controls are described in Table 1. It is important to
emphasize that this study was set up to identify pheno-
types within our group of stable COPD patients and not
to study differences between COPD patients and healthy
individuals. No statistical differences were found for age,
BMI or hsCRP; whereas the FEV1 and the FEV1/FVC
Fig. 1 Flowcytometry gating strategy. Granulocytes and monocytes were identified according to forward and sideward scatter signal. Neutrophils
and eosinophils were identified according their CD16 expression
Table 1 Patient characteristics
Characteristics Controls
(N = 7)
COPD
(N = 41)
Statistics
Age, yrs 60 ± 6 60 ± 8 0.929
Gender
Male 5 30
Female 2 11
FEV1, L 3.4 ± 1.0 1.6 ± 1.0 < 0.001
FEV1, % predicted 109 ± 21 50 ± 26 < 0.001
FEV1/FVC ratio 77 ± 4 41 ± 13 < 0.001
GOLD
I 8
II 8
III 12
IV 13
MRC dyspnoe scale
0 7 1
1 10
2 12
≥ 3 18
Smoking status
Current smoker 14
Ex-smoker 3 27
Never smoker 4
BMI, kg/m2 24 ± 1.4 24 ± 3.3 0.790
hsCRP 3.8 ± 5.4 4.6 ± 6.9 0.765
Leukocyte count 6.2 ± 1.9 7.7 ± 1.8 0.052
Continues data are shown as mean ± SD
FEV1 Forced Expiratory Volume 1, FVC Forced Vital Capacity, MRC Medical
Research Council, GOLD Global Initiative for Chronic Obstructive Pulmonary
Disease, BMI Body mass index
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were statistically different between the COPD patients
and the controls. Although the leukocyte counts of the
COPD patients were not significantly different from the
controls, the COPD patients have a higher leukocyte
count than the controls (p = 0.05). This could implicate
that there is an ongoing but low systemic inflammation
in the COPD patients.
2D-DIGE analysis of peripheral neutrophils from controls
and COPD patients
We performed 2D-DIGE with peripheral neutrophils
isolated from peripheral blood of healthy age matched
controls and COPD patients. All protein samples were
labelled with CyDye and separated by 2D-DIGE in differ-
ent experiments. Upon analysis 1200–2400 protein spots
were identified by the DeCyder 7.0 software. Here a vol-
ume filter exclusion was used of 30 000 in the Difference
In-gel Analysis (DIA) software. The individual spot maps
were matched in the Biological Variation Analysis (BVA)
Software. We matched 2058 protein spots, of which 875
proteins were present in >70% of the spot maps. Statis-
tical analysis between healthy age-matched controls and
COPD patients showed 21 proteins spots that were at
least 1.5 fold differentially regulated with a p < 0.05
(Fig. 2). Based on these 21 differentially regulated pro-
teins the peripheral neutrophil spot maps from COPD
patients could be separated from healthy age-matched
controls by principal component analysis (PCA) (Fig. 3).
Hierarchical clustering of COPD and healthy control
samples based on differential protein expression
We observed differential protein expression in peripheral
blood neutrophils between COPD patients and healthy
age-matched controls using 2D-DIGE. We combined all
differentially regulated proteins using the EDA in the
DeCyder 7.0 software package and performed a hierarch-
ical clustering analysis. Based on the 21 differentially
expressed proteins we observed two groups in this way
(Fig. 4a). COPD group 1 consists of a mix of healthy age-
matched control and COPD spot maps, whereas COPD
group 2 comprised solely COPD spot maps. The COPD
patients which were mixed with the healthy age-matched
controls (COPD group 1) in the hierarchical clustering
were indicated (blue dots) in the PCA analysis of the 21
differentially expressed proteins (Fig. 4b).
No differences in clinical parameters between COPD
group 1 and COPD group 2
The hierarchical clustering showed a group that resem-
bled neutrophils of healthy age-matched controls (COPD
group 1) and a distinct group of COPD patients (COPD
group 2) based on their differential protein expression.
When we compared the lung function data (FEV1, FEV1/
FVC) between COPD patients in group 1 with the patients
in group 2 there were no significant differences (Table 2).
Therefore, the difference in peripheral neutrophil prote-
ome identified by hierarchical clustering of spot maps did
Fig. 2 2D-DIGE gel with the 21 differentially expressed proteins. Protein samples were focused on 24 cm pH3-10NL IEF strips and separated by
12% SDS-PAGE. The indicated spots represent the differentially regulated proteins identified by Decyder 7.0 analysis software
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not correspond to the current classification of COPD
based on FEV1 and FEV1/FVC. Also the hsCRP values
and the total leukocyte counts were not significantly dif-
ferent between the two COPD groups (Table 2). Other
clinical parameters are described in Table 2; these were
also not significantly different between the two groups of
COPD patients.
Single activation markers on peripheral neutrophils are
not significantly different between COPD group 1 and
COPD group 2
Although the neutrophils proteome was different between
the two COPD groups; the expression of several activation
markers were not significantly different (Table 3 and
Fig. 5). The expression was measured on native non-
activated neutrophils. The activation markers Mac-1,
CD66b and CXCR1 were similar between the two groups.
Although the active FcγRII appeared to be higher in
COPD group 2, it did not reach statistical significance.
Differences in cytokine levels between COPD group 1 and
COPD group 2
We measured the levels of a number of cytokines but only
a few were significantly different between the two COPD
groups or between COPD and healthy age-matched con-
trols (Fig. 6). The cytokine IL13 and the chemokines
CCL11 and CXCL8 were significantly different between
COPD group 1 and 2 (Fig. 6b–d), whereas IL10 and
CXCL8 (Figs. 4d, 6a) were significantly different between
COPD group 2 and the healthy age-matched controls.
The cytokines CCL11, chemerin and resistin (Fig. 6c, e–f )
were different between COPD group 1 and the healthy
age-matched controls.
Reduced ROS production in COPD group 2
The peripheral neutrophils from COPD group 2 had lower
respiratory burst (ROS production) compared to the neu-
trophils from COPD group 1 (Fig. 7a–b). This was also
the case for eosinophils (Fig. 7c–d) and monocytes
(Fig. 7e–f ). The respiratory burst of peripheral neutrophils
after fMLF stimulation in controls was higher compared
to COPD group 2 and lower compared to COPD group 1
(Fig. 7a–b).
Discussion
It has been well accepted that there is only a very poor
relation between the GOLD stages and clinical manifes-
tations such as symptoms and the health status of COPD
patients [5, 6]. COPD is a heterogeneous disease that is
characterized by both pulmonary and extra-pulmonary
manifestations and the GOLD classification does not in-
clude the extra-pulmonary components of this disease.
Fig. 3 COPD spot maps were discriminative in a principal component analysis. Data of the 21 significant differentially regulated proteins (blue
spots in the loading plot) in the Biological Variation Analysis (BVA) of peripheral neutrophils from COPD patients were imported in the extended
data analysis (EDA) software. Principal component analysis (PCA) was performed on 41 COPD (red dots) and 7 age-matched control (green dots)
spot maps
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We tested the hypothesis that multiple COPD phenotypes
exist and that these are characterized by differences in sys-
temic inflammation. The biological effect and the role in
systemic inflammation of single cytokines is difficult to
objectify, because of the fast changes in their dynamics/
kinetics in the peripheral blood. Also functional cross-talk
between different cytokines has been observed, which
makes the effect of a pool of cytokines even more difficult
to predict. We have shown that pro-inflammatory TNFα
can induce enhanced CD83 expression on human neutro-
phils and that another pro-inflammatory cytokine, GM-
CSF, can antagonize this effect [20]. Therefore, we used
differences in peripheral neutrophils as a read out for
systemic inflammation as these cells integrate pro- and
anti-inflammatory signals into a specific activation pheno-
type. We applied the unbiased proteomics approach to
define these activation phenotypes. We compared protein
expression of peripheral neutrophils from 41 COPD pa-
tients and 7 healthy age-matched controls using our 2D-
DIGE approach. With the use of the DeCyder 7.0 software
we were able to identify 21 differentially regulated proteins
(>1.5 fold and p < 0.05) (Fig. 2). Based on the differential
expression of these proteins we performed a principle
component analysis (PCA) and a hierarchical clustering.
Fig. 4 a-b Hierarchical clustering control and COPD spot maps and principal component analysis. Twenty one differentially regulated proteins
were identified with the Decyder 7.0 analysis software and used for hierarchical clustering in the extended data analysis (EDA) of the Decyder 7.0.
Clustering of the differentially regulated protein expressed (red is up-regulated, green is down-regulated) revealed two groups of spot maps. Group 1
were mixed COPD and age-matched healthy control spot maps and Group 2 solely comprised COPD spot maps. The COPD spot maps in group 1
were designated as COPD group 1 and the COPD spot maps in group 2 were designated as COPD group 2 (a). The COPD group 1 spot maps in the
Principal component analysis based on the 21 significant differentially regulated proteins were depicted in blue. Whereas the COPD group 2 spot maps
were depicted in red and the age-matched controls were depicted in green (b)
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There is a clear distinction between the neutrophil
proteome of the healthy age-matched controls and the
COPD patients, albeit not the focus of this study
(Fig. 3). Our data replicate our earlier results showing
similar differences [25] in spot maps of neutrophils
from a small group of COPD patients and age-matched
controls.
A limitation in our study is that about 60% of the
healthy age-matched controls were never smokers;
whereas COPD is a smoking related disease. In our earlier
study [25] spot maps from COPD patients were compared
with control spot maps of either ex-smokers or non-
smokers in a PCA and still showed clustering of COPD
spot maps apart from the control spot maps. Apparently,
COPD specific signals could be identified irrespective of
the smoking habits of the control groups.
Using the differentially expressed proteins in a hierar-
chial clustering, we could identify two different clusters.
One cluster only existed of COPD patients while the
second cluster coexisted of both COPD patients and age-
matched controls (Fig. 4a). The existence of the two
COPD groups identified by the 2D-DIGE approach sug-
gest that peripheral neutrophils were differentially affected
by systemic inflammatory processes in vivo, probably by
different combinations of pro-and anti-inflammatory
mediators.
We sought to find differences in clinical and immuno-
logical parameters between the two COPD groups. We
were unable to find statistical differences in lung func-
tion (FEV1, FEV1/FVC) (Table 2). Therefore, it is un-
likely that the lung function was related to the proteome
of the peripheral neutrophils. This fits with other studies
including ECLIPSE [26, 27] that failed to demonstrate a
correlation between systemic inflammation and lung
function in at inclusion stable COPD patients. Interest-
ingly hsCRP, which is known as a marker for systemic
inflammation, was not statistically different between the
two COPD groups and/or GOLD stages. This is also in
line with previous studies [28, 29]. These data add to a
growing understanding that if systemic inflammation is
an important constituent of the pathogenesis of stable
COPD, this process cannot be adequately determined by
either GOLD classification nor changes in hsCRP levels.
In contrast to stable COPD, the situation with exacerba-
tions is different as high CRP levels have been found in
COPD patients under these conditions [30–32].
Our data regarding the absence of differences in ex-
pression of CD11b and CXCR1 on neutrophils (Table 3)
contrast findings published by others [33, 34]. Although
the COPD patients in the studies of Yamagata et al. [34]
and Noguera et al. [33] were stable, the expression of
CD11b and CXCR1 on neutrophils was measured on
isolated neutrophils. Kuijpers et al. [35] have shown that
isolation induce activation of neutrophils, which is likely
more pronounced on primed cells such as found in our
COPD patients (see below). Others have also been un-
successful in finding enhanced levels of hsCRP in stable
COPD patients [28, 29]. Therefore, it seems that a low
grade systemic inflammation present in stable COPD
Table 2 Clinical data of COPD group 1 and COPD group 2
Clinical parameters COPD group 1
(N = 17)
COPD group 2
(N = 24)
Statistics
Age, yrs 59 ± 6 61 ± 9 0.367
FEV1, L 1.89 ± 1.27 1. 40 ± 0.69 0.167
FEV1, % predicted 56 ± 30 46 ± 22 0.259
FEV1/FVC ratio 44 ± 15 39 ± 12 0.214
Pack years 46 ± 18 38 ± 14 0.160
DLCO 56 ± 20 60 ± 21 0.531
P15, HU −946 ± 23 −953 ± 22 0.392
6MWD, m 472 ± 106 476 ± 131 0.904
Pack years 46 ± 18 38 ± 14 0.160
MRC dyspnoe scale 2.2 ± 1.1 2.6 ± 1.4 0.414
CCQ total score 2.1 ± 1.2 1.9 ± 1.1 0.696
SGRQ total score 44 ± 19 44 ± 17 0.899
BODE index 3.1 ± 2.7 3.4 ± 2.5 0.718
hsCRP 4.3 ± 5.4 4.9 ± 7.8 0.779
Leukocyte count 7.7 ± 1.6 7.7 ± 2.0 0.931
FEV1 Forced Expiratory Volume 1, FVC Forced Vital Capacity, DLCO Diffusion
capacity of the lung for carbon monoxide, P15 15th percentile, HU hounsfield
unit, 6MWD 6 min walking distance, CCQ Clinical COPD Questionnaire, SGRQ
St. George’s Respiratory Questionnaire
Table 3 The activation markers on (unstimulated) peripheral
neutrophils between COPD group 1 and COPD group 2
Activation markers COPD group 1
(N = 17)
COPD group 2
(N = 22)
Statistics
MFI Mean ± SD Mean ± SD
CD11b 85 ± 36 78 ± 64 0.699
CD18 96 ± 67 80 ± 31 0.371
CD64 38 ± 65 27 ± 31 0.493
CD66b 75 ± 36 78 ± 34 0.762
Active FcγRII 65 ± 68 120 ± 239 0.367
CD32 214 ± 52 233 ± 34 0.136
CXCR1 190 ± 58 188 ± 49 0.936
CD62L 255 ± 234 194 ± 75 0.317
CD45 10 ± 4.86 11 ± 4.12 0.541
CXCR2 64 ± 17 67 ± 30 0.920
CD35 31 ± 15 32 ± 21 0.310
CD15 958 ± 363 1171 ± 519 0.920
CD63 4.02 ± 0.78 4.46 ± 1.42 0.920
CD44 541 ± 114 579 ± 163 0.152
N29 17 ± 4 19 ± 11 0.920
MFI median fluorescence intensity, SD standard deviation
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patients did not lead to an increased expression of
CD11b, CXCR1 or hsCRP.
The systemic inflammation in our COPD cohort was as-
sociated with minor differences in the presence of sys-
temic mediators (Fig. 6). We first focused on changes in
serum TNFα as differences in the presence of this cyto-
kine has been found previously [17, 36, 37]. We failed to
detect differences in levels of TNFα between the controls
and the COPD patients which were also not found in
ECLIPSE. In this study TNFα appeared to be primarily a
marker of smoking and not of COPD [27]. In addition, we
found no difference in TNFα between the two COPD
groups (data not shown). These data question an import-
ant role of systemic TNFα in the pathogenesis of stable
COPD. This conclusion is supported by our previous
study that [25] showed that the proteomes of peripheral
Fig. 5 Histogram overlays of the expression of all used markers on neutrophils from COPD group 1 and COPD group 2. Representative example
of the subtle changes in expression of different markers on neutrophils isolated from patient blood of the different COPD groups. Isotype controls are
shown in red and purple for cells of COPD 1 and COPD 2, respectively. For statistics see Table 3
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neutrophils of COPD patients were not similar to periph-
eral neutrophils that were stimulated in vitro by TNFα.
The only differences in cytokine levels between the two
COPD groups were found for IL13 and chemokines
CCL11/eotaxin, CXCL8/IL-8 (Fig. 6b–d). This might indi-
cate that both the systemic eosinophils (IL-13/Eotaxin) as
well as the systemic neutrophil (CXCL8/IL-8) compart-
ment are affected in stable COPD without changes in the
aforementioned characteristics of the cells.
The above mentioned data prompted us to analyse
more subtle changes in granulocyte physiology and
analysed the functionality of the cells in the context of
activation of the respiratory burst. Neutrophils carefully
isolated from normal control individuals are character-
ized by a low fMLF-induced respiratory burst as this
response needs priming by agonists such as PAF that by
themselves are poor activators of this response. The
relative fMLF response in isolated cells compared to
Fig. 6 Cytokine differences between the two COPD groups and the age-matched controls. Plots with the mean plasma levels of IL10, IL13, CCL11,
CXCL8, Chemerin and Resistin (a-f) in age-matched controls (n = 6), COPD patient group 1 (n = 17) and COPD patient group 2 (n = 24). Cytokine levels
are expressed as Mean ± SEM. An ANOVA was used to perform statistics (* p < 0.05; ** p < 0.01 NS = not significant)
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PAF primed cells is a measure of neutrophil priming [38].
The respiratory burst (ROS production) of the peripheral
neutrophils of the two COPD groups were significantly
different (Fig. 7a–b). The fMLF-induced ROS production
of peripheral neutrophils from COPD group 1 patients
tended to be higher compared to controls; whereas the
ROS production of peripheral neutrophils from COPD
group 2 patients was lower. This difference in functional-
ity after fMLF stimulation between COPD group 1 and 2
was not only present in peripheral neutrophils but also in
Fig. 7 The respiratory burst (ROS production) assay. Leukocytes (2.0 10^6 cells/ml) of age-matched controls (n = 12), COPD patient groups 1 (n = 17)
and COPD patient group 2 (n = 19) were pre-incubated in the presence or absence of PAF (10−6 M); loaded with DHR 123 for 5 min and stimulated
with fMLF (a-f) for 15 min at 37 °C. Production of ROS was measured by oxidation of intracellular DHR 123 and measured using flow cytometry
(Mean ± SEM). An independent t-test (** = p < 0.01, * = p < 0.05) was used to perform statistical analysis
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eosinophils and monocytes (Fig. 7c–f ). These data fit the
hypothesis that COPD group 1 is characterized by the
presence of systemic neutrophils with a primed phenotype
(higher ROS production compared to healthy controls)
and COPD group 2 is characterized by cells with a hypo-
responsive phenotype. The underlying mechanisms might
be that COPD group 2 has systemic neutrophils with a
hypo-responsive phenotype, because hyper-responsive/
primed cells have migrated to the tissues leaving behind
more refractory cells in the circulation. However, this dif-
ference seen in the functionality of the cells did not lead
to differences in clinical manifestations, which were
measured in this study. More clinical data, better and
more subtle differences in innate immune cells, larger
cohorts of COPD patients and the identification of the
21 differentially expressed proteins will probably im-
prove the understanding of different COPD phenotypes
and the differences found in the functionality of periph-
eral neutrophils between the two groups.
Conclusion
We identified a distinct group of COPD patients, who
were different from healthy age-matched controls and
other COPD patients based on the proteome of peripheral
neutrophils. Lung function was not different between the
two COPD patient groups. However, the ROS production
of peripheral neutrophils was different in COPD group 1
compared to COPD group 2. These data are consistent
with the hypothesis that COPD patients are characterized
by subtle differences in systemic inflammation that cannot
be identified by classical markers. These differences are,
however, apparent when the functionality of the cells is
studied. Therefore, future studies on targeting systemic in-
flammation in stable COPD should focus on these subtle
difference and this difference should not rely only on the
classical markers such as individual cytokines, acute phase
proteins or single activation markers.
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